ReviewCurrent opinion in infectious diseases2009
New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo.
Review in Current opinion in infectious diseases, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- A novel synergistic phycobiliprotein combination against HIV-1 shows potent antiviral activity.AMB Express · 2026Article
- A Tripartite Complex HIV-1 Tat-Cyclophilin A-Capsid Protein Enables Tat Encapsidation That Is Required for HIV-1 Infectivity.Journal of virology · 2023Article
- Review
- Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Article
- HIV-1 CNS in vitro infectivity models based on clinical CSF samples.The Journal of antimicrobial chemotherapy · 2016Article
- An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.International journal of pharmaceutics · 2015Article
- Toward the development of a single-round infection assay based on EGFP reporting for anti-HIV-1 drug discovery.Reports of biochemistry & molecular biology · 2015Article
- Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.Antimicrobial agents and chemotherapy · 2015Article
- Optimized Infectivity of the Cell-Free Single-Cycle Human Immunodeficiency Viruses Type 1 (HIV-1) and Its Restriction by Host Cells.PloS one · 2013Article
- An intravaginal ring for the simultaneous delivery of multiple drugs.Journal of pharmaceutical sciences · 2012Article
- Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings.AIDS (London, England) · 2012Article
- Phenotypic analysis of HIV-1 genotypic drug-resistant isolates from China, using a single-cycle system.Molecular diagnosis & therapy · 2011Article
- Kinetics of the viral cycle influence pharmacodynamics of antiretroviral therapy.Biology direct · 2011Article
- Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Clinical pharmacokinetics · 2011Review
- EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitors.Antimicrobial agents and chemotherapy · 2010Article
- Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2010Article
- Human Herpesviruses as Copathogens of HIV Infection, Their Role in HIV Transmission, and Disease Progression.Journal of laboratory physiciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewWith highly active antiretroviral therapy, HIV-1 infection has become a manageable lifelong disease. Developing optimal treatment regimens requires understanding how to best measure anti-HIV activity in vitro and how drug dose-response curves generated in vitro correlate with in-vivo efficacy. RECENT
findingsSeveral recent studies have indicated that conventional multiround infectivity assays are inferior to single cycle assays at both low and high levels of inhibition. Multiround infectivity assays can fail to detect subtle but clinically significant anti-HIV activity. The discoveries of the anti-HIV activity of the hepatitis B drug entecavir and the herpes simplex drug acyclovir were facilitated by single-round infectivity assays. Recent studies using a single-round infectivity assay have shown that a previously neglected parameter, the dose-response curve slope, is an extremely important determinant of antiviral activity. Some antiretroviral drugs have steep slopes that result in extraordinary levels of antiviral activity. The instantaneous inhibitory potential, the log reduction in infectivity in a single-round assay at clinical drug concentrations, has been proposed as a novel index for comparing antiviral activity. SUMMARY: Among in-vitro measures of antiviral activity, single-round infection assays have the advantage of measuring instantaneous inhibition by a drug. Re-evaluating the antiviral activity of approved HIV-1 drugs has shown that the slope parameter is an important factor in drug activity. Determining the instantaneous inhibitory potential by using a single-round infectivity assay may provide important insights that can predict the in-vivo efficacy of anti-HIV-1 drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.